CISO · CISO Global, Inc. · Insider Trading

On June 13, 2025 (the "Grant Date"), the reporting person was granted a Restricted Stock Unit grant for 400,000 shares of common stock (the "2025 RSU"). Each restricted stock unit represented a contingent right to receive one share of issuer's common stock. The 2025 RSU vested with respect to 25% of the underlying shares on June 13, 2026, and 6.25% has vested and shall vest at the end of each three-month period following the first anniversary of the Grant Date, such that 100% shall be vested on the fourth anniversary of the Grant Date.

On June 13, 2025 (the "Grant Date"), the reporting person was granted a Restricted Stock Unit grant for 750,000 shares of common stock (the "2025 RSU"). Each restricted stock unit represented a contingent right to receive one share of issuer's common stock. The 2025 RSU vested with respect to 25% of the underlying shares on June 13, 2026, and 6.25% has vested and shall vest at the end of each three-month period following the first anniversary of the Grant Date, such that 100% shall be vested on the fourth anniversary of the Grant Date.

On June 13, 2025 (the "Grant Date"), the reporting person was granted a Restricted Stock Unit grant for 750,000 shares of common stock (the "2025 RSU"). Each restricted stock unit represented a contingent right to receive one share of issuer's common stock. The 2025 RSU vested with respect to 25% of the underlying shares on June 13, 2026, and 6.25% has vested and shall vest at the end of each three-month period following the first anniversary of the Grant Date, such that 100% shall be vested on the fourth anniversary of the Grant Date.

On June 13, 2025 (the "Grant Date"), the reporting person was granted a Restricted Stock Unit grant for 400,000 shares of common stock (the "2025 RSU"). Each restricted stock unit represented a contingent right to receive one share of issuer's common stock. The 2025 RSU vested with respect to 25% of the underlying shares on June 13, 2026, and 6.25% has vested and shall vest at the end of each three-month period following the first anniversary of the Grant Date, such that 100% shall be vested on the fourth anniversary of the Grant Date.

On June 13, 2025 (the "Grant Date"), the reporting person was granted a Restricted Stock Unit grant for 750,000 shares of common stock (the "2025 RSU"). Each restricted stock unit represented a contingent right to receive one share of issuer's common stock. The 2025 RSU vested with respect to 25% of the underlying shares on June 13, 2026, and 6.25% has vested and shall vest at the end of each three-month period following the first anniversary of the Grant Date, such that 100% shall be vested on the fourth anniversary of the Grant Date.

On June 13, 2025 (the "Grant Date"), the Reporting Person was granted a Restricted Stock Unit grant for 400,000 shares of common stock (the "2025 RSU"). Each restricted stock unit represented a contingent right to receive one share of issuer's common stock. The 2025 RSU will vest with respect to 25% of the underlying shares on June 13, 2026, and 6.25% shall vest at the end of each three-month period following the first anniversary of the Grant Date, such that 100% shall be vested on the fourth anniversary of the Grant Date.

On June 13, 2026, the initial 25% of the 2025 RSU vested. A net number of 138,468 shares were issued.

On June 13, 2025 (the "Grant Date"), the reporting person was granted a Restricted Stock Unit grant for 750,000 shares of common stock (the "2025 RSU"). Each restricted stock unit represented a contingent right to receive one share of issuer's common stock. The 2025 RSU vested with respect to 25% of the underlying shares on June 13, 2026, and 6.25% has vested and shall vest at the end of each three-month period following the first anniversary of the Grant Date, such that 100% shall be vested on the fourth anniversary of the Grant Date.

On June 13, 2025 (the "Grant Date"), the reporting person was granted a Restricted Stock Unit grant for 400,000 shares of common stock (the "2025 RSU"). Each restricted stock unit represented a contingent right to receive one share of issuer's common stock. The 2025 RSU vested with respect to 25% of the underlying shares on June 13, 2026, and 6.25% has vested and shall vest at the end of each three-month period following the first anniversary of the Grant Date, such that 100% shall be vested on the fourth anniversary of the Grant Date.

On June 13, 2025 (the "Grant Date"), the reporting person was granted a Restricted Stock Unit grant for 400,000 shares of common stock (the "2025 RSU"). Each restricted stock unit represented a contingent right to receive one share of issuer's common stock. The 2025 RSU vested with respect to 25% of the underlying shares on June 13, 2026, and 6.25% has vested and shall vest at the end of each three-month period following the first anniversary of the Grant Date, such that 100% shall be vested on the fourth anniversary of the Grant Date.

On June 13, 2025 (the "Grant Date"), the Reporting Person was granted a Restricted Stock Unit grant for 400,000 shares of common stock (the "2025 RSU"). Each restricted stock unit represented a contingent right to receive one share of issuer's common stock. The 2025 RSU will vest with respect to 25% of the underlying shares on June 13, 2026, and 6.25% shall vest at the end of each three-month period following the first anniversary of the Grant Date, such that 100% shall be vested on the fourth anniversary of the Grant Date.

On June 13, 2026, the initial 25% of the 2025 RSU vested. A net number of 73,850 shares were issued.

On June 13, 2025, the reporting person was granted stock options exercisable for 500,000 shares of common stock (the "June 2025 Options"). The June 2025 Options vested with respect to 25% of the underlying shares on June 13, 2026, and thereafter has vested and shall vest at a rate of 1/36 per month beginning on July 14, 2026.

On June 13, 2025 (the "Grant Date"), the reporting person was granted a Restricted Stock Unit grant for 400,000 shares of common stock (the "2025 RSU"). Each restricted stock unit represented a contingent right to receive one share of issuer's common stock. The 2025 RSU vested with respect to 25% of the underlying shares on June 13, 2026, and 6.25% has vested and shall vest at the end of each three-month period following the first anniversary of the Grant Date, such that 100% shall be vested on the fourth anniversary of the Grant Date.

On June 13, 2025, (the "Grant Date") the Reporting Person was granted a Restricted Stock Unit grant for 750,000 shares of common stock (the "2025 RSU"). Each restricted stock unit represents a contingent right to receive one share of issuer's common stock.

The 2025 RSU grant shall vest with respect to 25% on the first anniversary of the Grant Date and 6.25% shall vest at the end of each three-month period following the first anniversary of the Grant Date, such that 100% shall be vested on the fourth anniversary of the Grant Date.

On May 13, 2025, the Reporting Person was granted two stock options each exercisable for 100,000 shares of common stock (the "May 2025 Options"). The May 2025 Options will vest with respect to 100% of the underlying shares on May 13, 2026.

On May 13, 2025, the Reporting Person was granted two stock options each exercisable for 100,000 shares of common stock (the "May 2025 Options"). The May 2025 Options will vest with respect to 100% of the underlying shares on May 13, 2026.

Represents the original principal amount of the 10.0% Unsecured Convertible Note (the "Note") and excludes interest that may accrue. Interest on the Note is payable monthly at a rate of 10.0% per annum. At any time prior to or on the maturity date of the Note, and subject to certain beneficial ownership limitations, the Reporting Person may convert all or any portion of the outstanding principal amount of the Note and all accrued and unpaid interest thereon into shares of common stock, par value $0.00001 per share, of the Issuer at a conversion price of $1.20 per share. The conversion price is subject to adjustment for subdivision or consolidation of shares and other standard dilutive events.

The Reporting Person is the President and Chief Operating Officer of Hensley & Company. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

The transactions reported herein reflect a repricing of the Options effective on August 22, 2022, resulting in the cancellation of the Options and the grant of replacement options. The exercise price of the Options was reduced from $5.42 to $3.02 per share. All of the other terms of the Options remain the same, including without limitation, the number of shares underlying the Options, the vesting period of the Options, and the expiration date of the Options.

On March 21, 2022, the Reporting Person was granted stock options exercisable for 1,000,000 shares of common stock (the "Options"). The Options will vest with respect to 25% of the underlying shares on March 21, 2023, and thereafter at a rate of 1/36 per month.

The transactions reported herein reflect a repricing of the options effective on August 22, 2022, resulting in the cancellation of the options and the grant of replacement options. The exercise price of the options was reduced from $3.50 to $3.02 per share. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting period of the options, and the expiration date of the options.

On February 28, 2022, the Reporting Person was granted stock options exercisable for 500,000 shares of common stock. The options will vest with respect to 25% of the underlying shares on February 28, 2024, and thereafter at a rate of 1/36 per month.

The transactions reported herein reflect a repricing of the Options effective on August 22, 2022, resulting in the cancellation of the Options and the grant of replacement options. The exercise price of the Options was reduced from $5.42 to $3.02 per share. All of the other terms of the Options remain the same, including without limitation, the number of shares underlying the Options, the vesting period of the Options, and the expiration date of the Options.

On March 21, 2022, the Reporting Person was granted stock options exercisable for 1,000,000 shares of common stock (the "Options"). The Options will vest with respect to 25% of the underlying shares on March 21, 2023, and thereafter at a rate of 1/36 per month.

The transactions reported herein reflect a repricing of the options effective on August 22, 2022, resulting in the cancellation of the options and the grant of replacement options. The exercise price of the options was reduced from $3.50 to $3.02 per share. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting period of the options, and the expiration date of the options.

On February 28, 2022, the Reporting Person was granted stock options exercisable for 500,000 shares of common stock. The options will vest with respect to 25% of the underlying shares on August 31, 2023, and thereafter at a rate of 1/36 per month.

The transactions reported herein reflect a repricing of the options effective on August 22, 2022, resulting in the cancellation of the options and the grant of replacement options. The exercise price of the options was reduced from $3.50 to $3.02 per share. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting period of the options, and the expiration date of the options.

On February 28, 2022, the Reporting Person was granted stock options exercisable for 500,000 shares of common stock. The options will vest with respect to 25% of the underlying shares on February 28, 2024, and thereafter at a rate of 1/36 per month.

The transactions reported herein reflect a repricing of the 2022 Options effective on August 22, 2022, resulting in the cancellation of the 2022 Options and the grant of replacement options. The exercise price of the 2022 Options was increased from $2.00 to $3.02 per share. All of the other terms of the 2022 Options remain the same, including without limitation, the number of shares underlying the 2022 Options, the vesting period of the 2022 Options, and the expiration date of the 2022 Options.

On January 14, 2022, the Reporting Person was granted stock options exercisable for 500,000 shares of common stock (the "2022 Options"). The 2022 Options will vest with respect to 30% of the underlying shares on January 31, 2023, and thereafter at a rate of 1/24 per month.

The transactions reported herein reflect a repricing of the options effective on August 22, 2022, resulting in the cancellation of the options and the grant of replacement options. The exercise price of the options was reduced from $3.50 to $3.02 per share. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting period of the options, and the expiration date of the options.

On February 28, 2022, the Reporting Person was granted stock options exercisable for 1,000,000 shares of common stock. The options will vest with respect to 25% of the underlying shares on February 28, 2023, and thereafter at a rate of 1/36 per month.

The transactions reported herein reflect a repricing of the options effective on August 22, 2022, resulting in the cancellation of the options and the grant of replacement options. The exercise price of the options was reduced from $3.50 to $3.02 per share. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting period of the options, and the expiration date of the options.

On February 28, 2022, the Reporting Person was granted stock options exercisable for 1,000,000 shares of common stock. The options will vest with respect to 25% of the underlying shares on February 28, 2023, and thereafter at a rate of 1/36 per month.

The transactions reported herein reflect a repricing of the 2022 Options effective on August 22, 2022, resulting in the cancellation of the 2022 Options and the grant of replacement options. The exercise price of the 2022 Options was increased from $2.00 to $3.02 per share. All of the other terms of the 2022 Options remain the same, including without limitation, the number of shares underlying the 2022 Options, the vesting period of the 2022 Options, and the expiration date of the 2022 Options.

On January 14, 2022, the Reporting Person was granted stock options exercisable for 500,000 shares of common stock (the "2022 Options"). The 2022 Options will vest with respect to 30% of the underlying shares on January 31, 2023, and thereafter at a rate of 1/24 per month.

The transactions reported herein reflect a repricing of the options effective on August 22, 2022, resulting in the cancellation of the options and the grant of replacement options. The exercise price of the options was reduced from $3.50 to $3.02 per share. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting period of the options, and the expiration date of the options.

On February 28, 2022, the Reporting Person was granted stock options exercisable for 500,000 shares of common stock. The options will vest with respect to 25% of the underlying shares on August 31, 2023, and thereafter at a rate of 1/36 per month.

On March 21, 2022, the Reporting Person was granted stock options exercisable for 1,000,000 shares of common stock (the "Options"). The Options will vest with respect to 25% of the underlying shares on March 21, 2023, and thereafter at a rate of 1/36 per month.

On February 28, 2022, the Reporting Person was granted stock options exercisable for 500,000 shares of common stock. The options will vest with respect to 25% of the underlying shares on February 28, 2024, and thereafter at a rate of 1/36 per month.

On February 28, 2022, the Reporting Person was granted stock options exercisable for 1,000,000 shares of common stock. The options will vest with respect to 25% of the underlying shares on February 28, 2023, and thereafter at a rate of 1/36 per month.

On February 28, 2022, the Reporting Person was granted stock options exercisable for 500,000 shares of common stock. The options will vest with respect to 25% of the underlying shares on August 31, 2023, and thereafter at a rate of 1/36 per month.

On January 14, 2022, the Reporting Person was granted stock options exercisable for 500,000 shares of common stock (the "2022 Options"). The 2022 Options will vest with respect to 30% of the underlying shares on January 31, 2023, and thereafter at a rate of 1/24 per month.

On December 31, 2021, the Reporting Person was granted stock options exercisable for 5,000 shares of common stock (the "2021 Options"). The 2021 Options will vest with respect to 25% of the underlying shares on December 31, 2022, and thereafter at a rate of 1/36 per month.

Represents the original principal amount of the 6.0% Unsecured Convertible Note (the "Note") and excludes interest. Interest on the Note was payable monthly at a rate of 6.0% per annum. At any time prior to or on the maturity date of the Note, and subject to certain beneficial ownership limitations, the Reporting Person had the right to convert all or any portion of the outstanding principal amount of the Note and all accrued and unpaid interest thereon into shares of common stock, par value $0.00001 per share, of the Issuer at a conversion price of $2.00 per share. The conversion price was subject to adjustment for subdivision or consolidation of shares and other standard dilutive events.

The Reporting Person is the President and Chief Operating Officer of Hensley & Company. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

The Reporting Person is the President and Chief Operating Officer of Hensley & Company. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

On May 5, 2021, the Reporting Person was granted stock options exercisable for 200,000 shares of common stock. The options will vest at a rate of 1/24 per month.

Represents the original principal amount of the 6.0% Unsecured Convertible Note (the "Note") and excludes interest. Interest on the Note was payable monthly at a rate of 6.0% per annum. At any time prior to or on the maturity date of the Note, and subject to certain beneficial ownership limitations, the Reporting Person had the right to convert all or any portion of the outstanding principal amount of the Note and all accrued and unpaid interest thereon into shares of common stock, par value $0.00001 per share, of the Issuer at a conversion price of $2.00 per share. The conversion price was subject to adjustment for subdivision or consolidation of shares and other standard dilutive events.

The Reporting Person is the President and Chief Operating Officer of Hensley & Company. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

The Reporting Person is the President and Chief Operating Officer of Hensley & Company. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.